-
Supreme Court ruling offers some clarity on biosimilar ‘patent dance’
WASHINGTON — In a decision that will have a big impact on the burgeoning biosimilars market, the Supreme Court on Monday overturned an appeals court decision which said Sandoz had to wait 180 days under federal law after receiving Food and Drug Administration approval to launch its biosimilar of Amgen’s Neupogen (filgrastim), Zarxio (filgrastim-sndz). The court did not rule out the possibility of state law allowing such an injunction, sending that question to a lower court.
-
CRN, AHPA to promote VMS with summertime 'Day on the Hill'
WASHINGTON — The Council for Responsible Nutrition and the American Herbal Products Association on Monday announced a cooperative advocacy effort for June 21. The event will bring together industry executives from across the country to visit with Congressional members and their staff to discuss the benefits of dietary supplements and functional food, the importance of industry’s products to their constituents' health and wellness and the economic impact of the industry.